Molecular basis of proteolytic activation of Sendai virus infection and the defensive compounds for infection

被引:5
作者
Kido, H [1 ]
Beppu, Y [1 ]
Sakai, K [1 ]
Towatari, T [1 ]
机构
[1] UNIV TOKUSHIMA,SCH MED,DEPT NUTR,TOKUSHIMA 770,JAPAN
关键词
mucus protease inhibitor; pulmonary surfactant; proleolytic activation; Sendai virus; tryptase Clara;
D O I
10.1515/bchm.1997.378.3-4.255
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It has been proposed that the pathogenicity of Sendai virus is primarily determined by a host cellular protease(s) that activates viral infectivity by proteolytic cleavage of envelope fusion glycoproteins. We isolated a trypsin-like serine protease, tryptase Clara, localized in and secreted from Clara cells of the bronchial epithelium of rats. The enzyme specifically cleaved the precursor of fusion glycoprotein FO of Sendai virus at residue Arg(116) in the consensus cleavage motif, Gln(Glu)-X-Arg, resulting in the presentation of the membrane fusion domain in the amino-terminus of the F1 subunit. Administration of an antibody against tryptase Clara in the airway significantly inhibited the activation of progeny virus and multiple cycles of viral replication, thus reducing the mortality rate. These findings indicate that tryptase Clara in the airway is a primary determinant of Sendai virus infection and that proteolytic activation occurs extracellularly. We identified two cellular inhibitory compounds against tryptase Clara in bronchial ravage. One was a mucus protease inhibitor, a major serine protease inhibitor of granulocyte elastase in the lining fluids of the human respiratory tract, and the other was a pulmonary surfactant which may adsorb the enzyme, resulting in its inactivation. These compounds inhibited virus activation by tryptase Clara in vitro and in vivo, but did not themselves affect the hemagglutination and the infectivity of the virus. The functional domain of the mucus protease inhibitor against the enzyme, which is organized in two homologous N- and C-terminal domains, is located in the C-terminal. Administration of these compounds in the airway may be useful for preventing infection with Sendai virus.
引用
收藏
页码:255 / 263
页数:9
相关论文
共 37 条
[31]   ORGAN TROPISM OF SENDAI VIRUS IN MICE - PROTEOLYTIC ACTIVATION OF THE FUSION GLYCOPROTEIN IN MOUSE ORGANS AND BUDDING SITE AT THE BRONCHIAL EPITHELIUM [J].
TASHIRO, M ;
YAMAKAWA, M ;
TOBITA, K ;
KLENK, HD ;
ROTT, R ;
SETO, JT .
JOURNAL OF VIROLOGY, 1990, 64 (08) :3627-3634
[32]   ISOLATION, PROPERTIES, AND COMPLETE AMINO-ACID-SEQUENCE OF HUMAN SECRETORY LEUKOCYTE PROTEASE INHIBITOR, A POTENT INHIBITOR OF LEUKOCYTE ELASTASE [J].
THOMPSON, RC ;
OHLSSON, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (18) :6692-6696
[33]   SEPARATION OF THE 2 DOMAINS OF HUMAN MUCUS PROTEINASE-INHIBITOR - INHIBITORY ACTIVITY IS ONLY LOCATED IN THE CARBOXY-TERMINAL DOMAIN [J].
VANSEUNINGEN, I ;
DAVRIL, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 179 (03) :1587-1592
[34]   ANTINEUTROPHIL ELASTASE DEFENSE OF THE NORMAL HUMAN RESPIRATORY EPITHELIAL SURFACE PROVIDED BY THE SECRETORY LEUKOPROTEASE INHIBITOR [J].
VOGELMEIER, C ;
HUBBARD, RC ;
FELLS, GA ;
SCHNEBLI, HP ;
THOMPSON, RC ;
FRITZ, H ;
CRYSTAL, RG .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (02) :482-488
[35]   CHARACTERIZATION OF AN ACID-STABLE PROTEINASE-INHIBITOR IN HUMAN CERVICAL-MUCUS [J].
WALLNER, O ;
FRITZ, H .
HOPPE-SEYLERS ZEITSCHRIFT FUR PHYSIOLOGISCHE CHEMIE, 1974, 355 (06) :709-715
[36]   ANTILEUKOPROTEASE-CONTAINING BRONCHIOLAR CELLS - RELATIONSHIP WITH MORPHOLOGIC DISEASE OF SMALL AIRWAYS AND PARENCHYMA [J].
WILLEMS, LNA ;
KRAMPS, JA ;
STIJNEN, T ;
STERK, PJ ;
WEENING, JJ ;
DIJKMAN, JH .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 139 (05) :1244-1250
[37]   FUNCTIONS OF THE N-TERMINAL DOMAIN OF SECRETORY LEUKOPROTEASE INHIBITOR [J].
YING, QL ;
KEMME, M ;
SIMON, SR .
BIOCHEMISTRY, 1994, 33 (18) :5445-5450